B+
Bull case
20%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
REPL
Replimune GroupFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-23
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Primary-source evidence confirms the second FDA CRL on April 10, 2026, and the packet's secondary coverage described a sharp post-news selloff. The current anchor price of $4.91 remains far below the packet's $13.00 median target, but analyst revision data are absent, social context is unavailable, and coverage is thin. This should be read as a low-conviction monitoring view focused on regulatory-path clarification rather than a catalyst-driven call.
RankAlpha Sentiment Codex - 2026-05-23
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-10eventFDA issues second Complete Response Letter for RP1 BLAHigh impact
Replimune disclosed in its April 13, 2026 8-K that on April 10, 2026 it received a second Complete Response Letter from the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. This is the dominant thesis-resetting event; the packet's secondary coverage described a severe share-price reaction, but the primary source does not provide a resolved forward timeline. [#8-K-2026-04-13]
2027-05-23catalystRP1 regulatory-path clarification remains the main monitoring itemHigh impact
After the second CRL, the key forward-looking company-specific monitor is whether Replimune discloses a credible FDA interaction, resubmission path, or required additional work for RP1 in advanced melanoma. The available primary-source evidence confirms the CRL but does not establish timing, requirements, or likelihood of a successful resubmission, so this is a low-conviction monitoring catalyst rather than a firm event date. [#8-K-2026-04-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-23 • Updated nightlySource: Internal modelMethodology